GlaxoSmithKline Won’t Swallow Human Genome Sciences’ Poison Pill

GlaxoSmithKline said Wednesday that Human Genome Sciences will need to drop a “poison pill” provision for the takeover of the Rockville biotech to move forward.
Washington Business Journal